Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding toVEGF(165) and VEGF(165)center dot KDR complexes
Y. Hamma-kourbali et al., Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding toVEGF(165) and VEGF(165)center dot KDR complexes, J BIOL CHEM, 276(43), 2001, pp. 39748-39754
We have previously shown that carboxymethyl dextran benzylamide (CMDB7), a
heparin-like molecule, inhibits the growth of tumors xenografted in nude mi
ce, angiogenesis, and metastasis by altering the binding of angiogenic grow
th factors, including platelet-derived growth factor, transforming growth f
actor beta, and fibroblast growth factor 2, to their specific receptors. In
this study, we explore the effect of CMDB7 on the most specific angiogenic
growth factor, vascular endothelial growth factor 165 (VEGF(165)). We demo
nstrate here that CMDB7 inhibits the mitogenic effect of VEGF(165) on human
umbilical vein endothelial cells (HUV-ECs) by preventing the VEGF(165)-ind
uced VEGF receptor-2 (KDR) autophosphorylation and consequently a specific
intracellular signaling. In competition experiments, the binding of I-125-V
EGF(165) to HUV-ECs is inhibited by CMDB7 with an IC50 of 2 muM. Accordingl
y, CMDB7 inhibits the cross-linking of I-125-VEGF(165), to the surface of H
UV-ECs, causing the disappearance of both labeled complexes, 170-180 and 24
0-250 kDa. We show that CMDB7 increases the electrophoretic mobility of VEG
F165, thus evidencing formation of a stable complex with this factor. Moreo
ver, CMDB7 reduces the I-125-VEGF(165) binding to coated heparin-albumin an
d prevents a heparin-induced increase in iodinated VEGF(165) binding to sol
uble I-125-KDR-Fc chimera. Concerning KDR, CMDB7 has no effect on I-125-KDR
-Fc electrophoretic migration and does not affect labeled KDR-Fc binding to
coated heparin-albumin. In the presence of VEGF(165), I-125-KDR-Fc binding
to heparin is enhanced, and under these conditions, CMDB7 interferes with
KDR binding. These data indicate that CMDB7 effectively inhibits the VEGF(1
65) activities by interfering with heparin binding to VEGF(165) and VEG(165
).KDR complexes but not by direct interactions with KDR.